IDO2 and cancer: Thus, treatment with a single agent may have a negligible suppressive effect on tumors, whereas cotreatment with other immunotherapy methods such as indoleamine 2,3-dioxygenase (IDO) inhibitors or anti-CTLA-4 can have a synergistic effect on cancer treatment and improve patient survival [48, 49].